The Role of CD38 in Predicting Outcomes for Non-M3 Acute Myeloid Leukemia Patients

Nasrin  Gholami; Roya  Dolatkhah; Ali Akbar  Movasaghpour Akbari; Arezoo  Fathalizadeh

doi:10.18502/jimc.v9i1.20494

Nasrin Gholami Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Roya Dolatkhah Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Ali Akbar Movasaghpour Akbari Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Arezoo Fathalizadeh Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

DOI: https://doi.org/10.18502/jimc.v9i1.20494

Keywords: Flow cytometry, Hematology, Humans, Iran, Leukemia, Myeloid, Acute, Prognosis, Retrospective studies, Survival rate

Abstract

Background: Acute Myeloid Leukemia (AML) is a rare but aggressive type of cancer with different survival rates around the world. While factors such as age, cytogenetic, and molecular abnormalities play an important role that impacts the prognosis of AML patients, the correlation between CD38 and other hematologic markers and the survival of AML patients for therapy initiation was investigated in this study.

Methods: In this retrospective cohort study, we relied on flow cytometry to examine CD38 expression on AML blasts and evaluated its correlation with Overall Survival (OS) and one-year survival in newly diagnosed AML patients at the Hematology-Oncology Research Center, Iran, Tabriz.

Results: Seventy-two newly diagnosed non M3-AML patients were followed in this study. The results showed there was a significant relationship between the OS and one year survival CD38 levels. Besides, increasing the CD38 level by 1% increased the hazard of mortality by 1 percent (HR=0.99; 95% CI: 0.98 to 1.01).

Conclusion: The expression of certain membrane molecules like CD38 on leukemic cells can provide valuable information about the prognosis of AML patients and their treatment options.